Moreover, AFP combine with ALT, AST, and NLR achieved significantly better diagnostic performance only in 40‐60 years patients for HBV‐HCC than AFP and any other combinations among different age patients, which might mean that application value of AFP is still not the best indicator in young or over 60‐year‐old patients. Here, AFP is linked to hepatocellular carcinoma.